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Amnestic mild cognitive impairment (aMCI) conversion to Alzheimer’s disease (AD) is seen in a 
sizable portion of aMCI patients; correlates predicting such conversion are poorly defined but 
neuroinflammation and the reactivation of chronic viral infections are suspected to play a role in this 
phenomenon. We analyzed these aspects in two homogeneous groups of aMCI who did or did not 
convert to AD over a 24-months period. Results showed that at baseline in those aMCI individuals who 
did not convert to AD: 1) Aβ1-42 stimulated production of the pro-inflammatory cytokines IL6 and IL1β 
by CD14+ cells was significantly reduced (p = 0.01), 2) CD14+/IL-33+ cells were increased (p = 0.0004); 3) 
MFI of TLR8 and TLR9 was significantly increased, and 4) better preserved hippocampus volumes were 
observed and correlated with IL33+/CD14+ cells. Notably, Aβ1-42 stimulated production of the antiviral 
cytokine IFN-λ was increased as well in non-AD converters, although with a borderline statistical 
significance (p = 0.05). Data herein indicating that proinflammatory cytokines are reduced, whereas 
IFN-λ production and TLR8 and 9 MFI are augmented in those aMCI in whom AD conversion is not 
observed suggest that the ability to mount stronger antiviral response within an antiiflammatory milieu 
associates with lack of AD conversion.
Mild cognitive impairment (MCI) is defined as a subjective and objective decline in cognitive performance that 
is greater than expected for an individual’s age and education level, but does not meet criteria for the diagnosis 
of dementia1–3. Elderly MCI patients are nevertheless at high-risk for developing dementia and, in particular, 
Alzheimer’s disease (AD)3–5. Recently, the International Working Group (IWG) introduced the terminology of 
MCI to refer to individuals with cognitive impairment that is not as severe as compared to what is seen in AD 
patients6. This situation thus represents a borderline condition between normal aging and AD7. Notably, although 
the diagnostic accuracy has certainly increased, correlates of MCI conversion to AD are still poorly defined.
The estimated annual rate of MCI conversion to AD ranges between 10% and 15%8, and MCI individuals 
in whom memory loss is the predominant symptom (amnestic MCI -aMCI-) are more prone to progress to 
AD. Predictive studies have described a number of biological and cognitive factors, including cognitive reserve9, 
performance in cognitive testing10, and the presence and concentration of biomarkers in the cerebrospinal fluid 
(CSF)11–13; that are suggested to correlate with AD conversion. Volumetric magnetic resonance imaging (MRI)14–16  
and fluorodeoxyglucose and Pittsburgh compound B positron emission tomography (FGD-PET, PIB-PET)17,18 
can also be useful in order to recognize those patients in whom AD conversion is more likely to occur. In par-
ticular, hippocampal volume as measured with MRI advanced techniques is a well-known biomarker of down-
stream neural degeneration or injury2. Although not suitable for defining preclinical AD-stage if considered as 
unique index, this downstream topological biomarker is adequate for the screening of subjects at risk, as recently 
stressed19.
The validity of these results is nevertheless hampered by the fact that most of published studies utilized a single 
marker to predict progression to AD9,10,14–16 even if this phenomenon is multifactorial. Such multidimensional-
ity,is reflected in the observation that a combination of MRI (hippocampal volumes)14–16, genetic (ApoE)20 and 
humoral (CSF levels of beta amyloid and phosporylated τ protein)11–13 indexes is currently suggested to have the 
greatest predictive value toward AD conversion.
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Genetic and environmental factors interact in the pathogenesis of AD, a complex and still scarcely understood 
process in which viral infections, and in particular Human Herpes Simplex virus type 1 infection (HSV-1) are 
suggested to play a role21–25. Microbial infections stimulate innate immunity via binding of the pathogen asso-
ciated molecular patterns (PAMPS) they express to toll like receptors (TLR). Nucleic acids produced upon viral 
replication, in particular, ligate TLR8 and 926,27 result in the activation of innate immunity and the production 
of multiple cytokines, amongst which interferon-lambda (IFN-λ) plays a pivotal role in limiting viral replication 
and the infection of target cells28. Recent results indicating that TLR expression is increased in immune cells of 
MCI individuals29,30 led to hypothesize that stronger immune responses to viruses could be detected in these 
individuals.
We analyzed whether immune correlates that predict MCI conversion into AD could be identified analyzing 
immunological parameters in a cohort of aMCI patients in whom AD conversion was or was not observed over 
a 24-months period. In addition, we also analyzed one of the MRI biomarker of AD-associated neural injury, the 
hippocampal volume.
Results herein suggest that stronger antiviral responses in the absence of inflammation is correlated to better 
preservation of the hippocampus volume and could predict AD conversion.
Results
Clinical characteristics of the individuals enrolled in the study. Demographic and clinical charac-
teristic of the individuals enrolled in the study are summarized in Table 1. As per inclusion criteria, no differences 
were observed in gender, age, years of education, global cognitive levels (MMSE) and ApoE4 status when AD 
converters and AD non-converters were compared at baseline.
TLR8 and TLR9 expressing CD14+ cells. CD14+ immune cells of AD converters and AD non-converters 
were either unstimulated or stimulated with TLR8 and 9 agonists (ODN and ssRNA, respectively), and the 
percentage of TLR-expressing cells was examined by flow-cytometry. Results showed that, whilst no differ-
ences were seen in unstimulated conditions (<1% of CD14+ cells expressed TLR8 or TLR9; data not shown), 
agonist-stimulated TLR8- and TLR9-expressing CD14+ cells were augmented, albeit not significantly, in AD 
non-converters (medians: TLR8 = 2.9%, TLR9 = 3.1%) compared to AD converter (medians: TLR8 = 1.6%, 
TLR9 = 2%; p = 0.06 in both cases) (Fig. 1). Notably, though, TLR8 and TLR9 Mean Fluorescence Intensity 
(MFI) was significantly increased in AD non-converters compared to AD converters (p = 0.0004, and p = 0.0001, 
respectively) (Table 2).
Pro-and anti-inflammatory cytokine mRNA expression in Aβ1-42 stimulated PBMC. Quantitative 
PCR analyses were performed in PBMC that were either cultured in medium alone or were stimulated with Aβ1-42 
(Fig. 2A). Results obtained in Aβ1-42– stimulated cells indicated that IL-1β and IL-6 mRNA was greatly reduced in 
AD non-converters compared to AD converters (IL1β > 200 fold; IL6 > 1000 fold; p = 0.04 and p = 0.05 respec-
tively). In contrast, no significant results (n-Fold change < 2) were obtained for IFN-λ 1,2,3 mRNA expression. 
Results also showed that IL-33 mRNA was robustly (>100 fold) increased in AD non-converters (Fig. 2A).
Pro-and anti-inflammatory cytokine production by Aβ1-42 -stimulated PBMC. Cytokine produc-
tion was measured by ELISA in supernatants of PBMC that were either unstimulated or were stimulated with 
Aβ1-42. Once again, no differences were observed in unstimulated conditions (data not shown). When Aβ1-42- stim-
ulated IL-1β and IL-6 production was measured, nevertheless, results showed that both these pro-inflammatory 
cytokines were significantly reduced in AD non-converters, compared to AD converters (p = 0.005 and p = 0.014 
respectively) (Fig. 2B). These results support the idea that the presence of an inflammatory milieu associates with 
AD conversion in individuals with a diagnosis of aMCI.
AD converters AD non-converters
Number (N) 25 21
Gender (M:F) 14:11 12:9
Age, years at baseline 76 ± 5.6 72 ± 6.2
Level of education, years 8.25 ± 2.71 7.62 ± 3.62
MMSE 25 ± 1.9 26 ± 2.1
MMSE after follow up 20 ± 5.1*# 25 ± 2.2
APOE ε-4 cariers (%) 20 20
L HV, mm3 2496 ± 560.2 3409.4 ± 402.5**#
R HV, mm3 2633.5 ± 492.6 3413.6 ± 496.4***#
Table 1. Demographic and clinical characteristics at baseline of the individuals enrolled in the study who had 
a diagnosis of amnestic mild cognitive impairment and did (AD converters) or did not (AD non-converters) 
convert to AD over a 24-months period. Mini-Mental State Evaluation (MMSE) after follow up indicates the 
value 24 months after the baseline result. *p = 0.003 between baseline and follow-up in AD-converters. **p = 0.04 
at baseline between AD converters and AD non-converters. ***p = 0.01 at baseline between AD converters and 
AD non-converters. #Power 1 − β ≥ 0.90 considering MMSE score or Hippocampal Volume (HV).
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IL-33 could not be measured in supernatants of Aβ1-42-stimulated PBMC, possibly because the mature form of 
this cytokine is not cleaved and secreted. Results obtained by flow-cytometry, nevertheless showed that CD14+/
IL-33+ cells were significantly increased in AD non-converters compared to AD converters (p = 0.0004) (Fig. 3B).
Antiviral cytokines: IFN-λ 1–3 production by Aβ1-42- stimulated PBMC. IFN-λ 1–3 production 
by unstimulated and Aβ1-42- stimulated PBMC was measured in all the individuals enrolled in the study. Results 
showed that Aβ1-42- stimulated IFN-λ 1–3-production was higher in AD non-converters compared to AD con-
verters (p = 0.05), suggesting that the ability to mount robust antiviral immune responses correlates with lack of 
progression to AD (Fig. 3C).
MRI results and correlations. High-resolution structural MRI acquisition was available at baseline in 27 
aMCI individuals, 13 of whom did (5 males, mean age 75 ± 6.3 years) and 14 of whom did not (6 males, mean 
age 73 ± 7.1 years) progress to AD. The two “MRI subgroups” (AD converters and AD non-converters) were 
comparable for age (two sample t-test, p = 0.4785) and gender (chi-square, p = 0.8731) at baseline. MRI volu-
metric measurements at baseline showed a trend indicating a better preservation of hippocampi volumes in AD 
non-converters, with a stronger effect when the right hippocampus was analyzed (AD non-converters vs. AD 
converters, left hippocampus (H-LV), F(1,27) = 13.7, p = 0.001 (and right hippocampus (H-RV), F(1,27) = 17.25, 
p = 0.004 (Fig. 3B).
Figure 1. TLR8 and TLR9 expressing CD14+ cells: TLR8- (upper panels) and TLR9- (lower panels) expressing 
CD14+ cells upon stimulation with specific agonists (ODN and ssRNA, respectively). Representative results in 
MCI individuals who did (AD-converters) or did not (AD non-converters) convert to AD over a 24-months 
period are presented in the left part of the figure; in the upper right corner the percentage of CD14/TLR8+ and 
CD14/TLR9+ cells is shown. Summary results were obtained in 21 AD converters and 25 AD non-converters 
and are shown in the bar graphs. The boxes stretch from the 25 to the 75 percentile; the line across the boxes 
indicates the median values; the lines stretching from the boxes indicate extreme values. Outside values are 
displayed as separate points.
AD converters
AD non-
converters p value
CD14+/TLR8+ 17.9 (16.6–19.1)a 36 (22.7–38.3) 0.0004
CD14+/TLR9+ 23.9 (19.6–25.9)a 43.3 (41.9–48.1) 0.0001
Table 2. Agonist-stimulated TLR8 and TLR9 mean fluorescence intensity (MFI) at baseline in CD14+ cells of 
patients with a diagnosis of amnestic mild cognitive impairment who did (AD converters) or did not (AD non-
converters) progress to Alzheimer’s disease over a 24-months period. Median (M) and Interquartile range (IQR) 
are shown. aTLR8 and TLR9 MFI calculated on MFI-positive cells alonen.
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Notably, the analyses of correlations indicated a significant positive association between CD14+/IL-33+ cells 
and the volumes of both left and right (p = 0.049 and p = 0.043 respectively) hippocampus in AD non-converters 
alone (Fig. 4). No significant differences were found when correlations between MRI results and other immuno-
logical parameters were evaluated.
Discussion
In mild cognitive impairment a slight but noticeable and measurable decline in cognitive abilities can be detected. 
Individuals with a diagnosis of MCI, and in particular those with a diagnosis of amnestic MCI (aMCI), have an 
increased risk of developing AD. Clinical, biological and imaging markers predicting MCI conversion to AD are 
still poorly clarified, possibly because the etiopathogenesis of AD itself is still barely understood. We analyzed 
immunologic and imaging markers in two groups of aMCI individuals who did or did not convert to AD over a 
24 months period. We described herein a combination of these markers that might be useful in predicting which 
patients will convert to AD.
We focused on imaging analyses of MRI-based measures of hippocampal volumes, one of the core diagnostic 
criteria for probable AD dementia2; thus we verified whether this parameter could be used as a biomarker to 
assess the presence of downstream neuronal degeneration or injury. Notably, hippocampal volume was recently 
suggested to be a possibly adequate index for the screening of subjects at risk of developing AD19,31.
Results showed that, besides being associated with a peculiar cytokine profile, lack of MCI conversion to 
AD in our aMCI individuals was also correlated with better preserved hippocampal volumes, with a more pro-
nounced effect in the right hippocampus. Importantly, better preserved hippocampal volumes were associated 
with higher percentages of circulating CD14+/IL-33+ cells in AD non-converters alone, suggesting a role for this 
cytokine in contrasting progression to AD in individuals with a diagnosis of aMCI. It is worth remarking that 
our analysis was adjusted for age, considering that increased variability in cognition with age has been argued as 
an indication of pathological processes32. These results support data indicating that MCI affects the size of the 
Figure 2. Pro-and- anti-inflammatory cytokine mRNA expression and protein in stimulated cells: (A) Aβ1-42-
stimulated IL-1β, IL-6 and IL-33 mRNA expression in MCI individuals who did (AD converters, N = 21) or 
did not (AD non-converters, N = 25) convert to AD over a 24-months period. Gene expression was calculated 
relative to GAPDH housekeeping gene. The expression of the genes is assessed by single real-time quantitative 
RT-PCR and shown as median of fold-change expression from the unstimulated samples. Summary results are 
shown in the bar graphs using TIGR Multi Experiment Viewer (MeV)v4.9. Aβ1-42-stimulated IL-1β and IL-6 
production (B); IL-33 expressing CD14+ cells (%) (C), and IFN-λ production (D) in PBMC of MCI individuals 
who did (AD converters; N = 21) or did not (AD non-converters; N = 25) convert to AD over a 24-months 
period. The boxes stretch from the 25 to the 75 percentile; the line across the boxes indicates the median values; 
the lines stretching from the boxes indicate extreme values. Outside values are displayed as separate points. 
Statistical significance is shown.
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hippocampus, and that this parameter, together with the rate of hippocampus shrinkage, can be useful in predict-
ing whether MCI does progress to AD33.
Viral infections, and in particular reactivation of HSV-1 infection34,35 are suggested to be involved in the 
pathogenesis of AD34; this hypothesis was recently reinforced by data indicating that accumulation of Aβ in the 
brain, the hallmark of AD, could play an antimicrobial role36. Immune defenses against viruses are initiated by 
ligation of TLR3, 8 and 9 by products of viral replication; this results in the production of cytokines with inflam-
matory and antiviral properties37. We and others have observed that the expression of TLRs that are engaged by 
viral PAMPs is up-regulated in CD14+ immune cells of MCI individuals30,38 possibly suggesting that stronger 
antiviral responses could be present in MCI. As a confirmation of this hypothesis, we show herein the presence 
of a significantly higher density of TLR8 and 9 on CD14+ cells in MCI patients that did not converter to AD, 
suggesting that a higher expression of viral PAMPs-specific immune sensors is associated with lack of disease 
progression.
Amongst the cytokines that were differentially modulated in AD converters and AD non-converters, and that 
are part of TLR-stimulated innate immune responses, IFN-λ stood out. IFN-λ includes at least three slightly dif-
ferent proteins that trigger mechanisms that contribute to the clearance of viral infections39,40 and, in particular, 
potently target HSV-141,42. We recently described the presence of a positive correlation between HSV-1-specific 
serum antibody titers and grey matter volumes in the brain area that are classically affected by AD43. It is thus 
tempting to speculate that stronger IFN-λ-mediated antiviral responses could play a role in avoiding progres-
sion to AD by impeding the excessive reactivation of viruses that persistently infect the CNS, possibly including 
HSV-1.
AD has been associated with neuroinflammation as the production of a number of pro-inflammatory 
cytokines is increased in cells of AD patients44. We observed that Aβ1-42-stimulated production of IL-1β and IL-6, 
in particular, discriminate between those aMCI individuals who progress to AD, and those in whom such pro-
gression is not observed. IL-1β has long been known to play a role in the pathogenesis of AD41,45. This cytokine 
promotes amyloid plaque deposition, induces a loss of phagocytic activity by the microglia, stimulates the hyper-
phosphorylation of τ protein, and affects synaptic plasticity46. As a consequence, IL-1β can impair learning and 
memory processes. IL-1β also recruits peripheral leukocytes to the brain parenchyma45. Peripheral monocytes 
are able to directly cross the BBB, both generating novel microglial cells and potentially further extending chronic 
neuroinflammation47. Since these cells are considered to be better at amyloid plaque removal than resident micro-
glia48, increases in IL-1β production were suggested to be a -possibly futile- attempt by the brain parenchyma to 
control β-amyloid accumulation. IL-6 concentration is also known to be increased both in animal models of AD 
Figure 3. Brain mask of aMCI-typical Hippocampus-region and MRI analysis: an example of automatic 
hippocampal segmentation using the ADABoost algorithm. Coronal, axial and sagittal brain views in a single 
subject are shown in the upper part (A); left (LH) and right (RH) hyppocampal volumes as evaluated by MRI 
in MCI individuals who did (AD converters, N = 13) or did not (AD non-converters, N = 14) convert to AD 
over a 24-months period. The boxes stretch from the 25 to the 75 percentile; the line across the boxes indicates 
the median values; the lines stretching from the boxes indicate extreme values. Outside values are displayed as 
separate points. Statistical significance is shown (B).
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and in patients49,50. Aβ directly stimulates the generation of IL-6 by human cortical neurons, playing a role in the 
production and the processing of amyloid precursor protein (APP). IL-6 also plays an important role in regu-
lating cognitive function. Thus: i) elevated IL-6 correlates with age-related cognitive decline in humans, and ii) 
excessive IL-6 production alters spatial learning and memory51,52. Our results indicate that higher IL-1β and IL-6 
production is detected in aMCI individuals converting into AD, reinforcing the idea that increased quantities of 
these inflammatory cytokines play a deleterious role in the development of AD.
IL-33 was also analyzed; this cytokine belongs to the IL-1β family and is a dual function protein with both 
intra and extra-cellular mechanisms of action. IL-33 can interact with the transcription factor NF-KB reducing 
NF-KB-triggered gene expression to dampen pro-inflammatory signalling53. Nuclear IL-33 can also induce the 
expression of intercellular and of vascular adhesion molecules for endothelial cell activation though binding to 
the p65 promoter54. Thus, IL-33 may have a role in regulating pathophysiology and inflammatory responses in the 
CNS55. IL-33 is reduced in AD brains, and this cytokine is believed to have a neuroprotective role secondary to the 
reduction of Aβ peptides secretion and the activation of their phagocytosis by the microglia56. The complexity of 
this cytokine is further underlined by recent results showing that three different polymorphism within the IL-33 
gene resulting in a protective haplotype are associated with risk of AD56. Notably, recent results showed that in the 
APP/PS1 mouse model of AD IL-33 polarizizes microglia/macrophage toward an anti-inflammatory phenotype 
and reduces the expression of proinflammatory cytokines, including IL-1β and IL-652,57. Indeed our results indi-
cate that increased amounts of IL-33 correlate with lower production of IL-1β and IL-6 in AD non-converters. 
Taken together, these results suggest that higher amounts of IL-33 in aMCI individuals in whom AD conversion 
is not observed is a successful strategy to reduce neuroinflammation.
All aMCI patients enrolled in the study were selected after retrospective analysis of a cohort of MCI patients; 
selection was based on the availability of neurocognitive evaluation at baseline and after 24 months, and of 
peripheral blood cells (PBMC) samples and brain MRI at baseline. Although the overall validity of our data is 
somewhat limited by the small number of patients analyzed, these results suggest that neuroinflammation, possi-
bly associated with weaker antiviral responses, plays a fundamental pathogenetic role in AD.
Methods
Patients. This study was approved by and carried out in accordance with the guidelines of the ethic commit-
tee of the Don Gnocchi Foundation. All participants or, if unable, their care-givers, gave informed consent to a 
protocol approved by the local ethics committee according to a protocol approved by the local ethics of the Don 
Gnocchi Foundation. The study conformed to the ethical principles of the Helsinki Declaration.
Figure 4. MRI analysis and correlations: Rank correlation between Aβ1-42 stimulated IL-33 producing CD14+ 
cells and the Left (L) and Right (R) hippocampus volume (HV) in MCI individuals who did (N = 13) or did not 
(N = 14) convert to AD. Statistical significance and Spearman’s coefficient of rank correlation (rho) are shown.
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A large cohort of MCI individuals is followed by the Unit of Rehabilitative Neurology at the Don C. Gnocchi 
Foundation in Milano, Italy; a portion of these individuals is affected by amnestic MCI (aMCI). The diagnosis 
of aMCI fulfills Grundman’s and Petersen’s operational criteria7,58. Within the aMCI cohort two homogeneous 
groups of subjects (21 AD converters and 25 AD non-converters) were selected for the study. Inclusion criteria 
were based on: a) availability of a clinical follow up for at least 24 months; b) neurocognitive evaluation (MMSE) 
at baseline as well as after follow-up; c) availability of PBMC samples at baseline; and d) availability of a 3D single 
high-resolution structural MRI acquisition at baseline in addition to conventional MRI scans (in this case data 
were available in 13 AD converters and 14 AD non- converters) at baseline. The clinical diagnosis of AD was 
performed according to the NINCDS-ADRDA work group criteria2. The study conformed to the ethical princi-
ples of the Helsinki Declaration. All patients or, if unable, their care-givers, gave informed consent to a protocol 
approved by the local ethics committee.
Blood sample collection and cell separation. Whole blood was collected by venipuncture in 
EDTA-containing Vacutainer tubes (Becton Dickinson & Co, Rutherford, NJ, USA). Peripheral blood mononu-
clear cells (PBMCs) were separated on lymphocyte separation medium (Ficoll-Hypaque, Organon Teknika Corp, 
Durham, NC, USA) and washed twice in PBS; viable leukocytes were determined using a TC20 Automated Cell 
Counter (Biorad Hercules,California, USA), PBMC were frozen and cold-preserved in liquid nitrogen in a cry-
oprotective media containing 10% dimethyl sulfoxide (DMSO) and fetal bovine serum (FBS). When needed for 
the experiments PBMC were thawed at 37 °C, washed in PBS and resuspended in RPMI 1640 to ensure optimal 
PBMC viability (>90%) for the cell culture.
Cell cultures. PBMC (1 × 106/ml) were cultured in RPMI 1640 supplemented with 10% human serum, 
2 mM L- glutamine, and 1% penicillin (Invitrogen, Ltd, Paisley, UK) and incubated at 37 °C in a humidified 5% 
CO2 atmosphere for 24 h. PBMC were stimulated with 10 μg/ml synthetic oligonucleotides containing unmeth-
ylated CpG dinucleotides (ODN); 2 μg/ml single-stranded RNA oligonucleotide (ssRNA); or Aβ1-42 (10 μg/ml)
(Sigma-Aldrich), St. Louis, MO or medium alone. Supernatants were used for cytokine detection; PBMC pellet 
were used for flow-cytometry analyses.
ApoE genotyping. Genomic DNA was isolated from whole blood by phenol-chloroform extraction. 
Customer-design Taqman probes for the 112 and 158 codons were used to determine the genotype of apolipo-
protein E gene (APOE)43.
RNA extraction and reverse transcription. RNA was extracted from unstimulated or Aβ1-42 
stimulated-PBMC and reverse transcribed into first-strand cDNA59,60. Real Time quantitative Reverse 
Transcription PCR (RQPCR) was performed using the ABI Prism 7000 instrument (PE Applied Biosystems, 
Foster City, CA, USA) with gene specific primers and SybrGreen chemistry described elsewhere59,60. The fol-
lowing cytokines were analyzed: IL-1β, IL-6, IL-33 (Qiagen, Hilden Germany) and IFNλ 1, 2, 3 (Sino Biological, 
LuDong Area, BDA China). Specific PCR products amplification was detected using the RT2 SYBR Green Fluor 
with a 25 μl final volume of 12.5 μl RT2 qPCR Mastermix (Qiagen), 10.5 μl H2O, 1.0 μl of either diluted template 
RT2 qPCR Primer Assay. Results were expressed as ΔΔCt and presented as ratios between the target gene and the 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) housekeeping mRNA. Experiments were individually run 
on each one of the individuals included in the study.
Flow cytometry immunofluorescent staining. PBMC were stained with anti-CD14-PC7 (clone 
RMO52, isotype mouse IgG2a, Beckman Coulter) and treated with the FIX and PERM Cell kit (eBioscience, San 
Diego, CA) before being stained with TLR8-PE (clone 610015, isotype mouse IgG1, R&D Systems), TLR9-FITC 
(clone M9.D6, isotype rat IgG2a, eBioscience), or IL33-APC (clone 390412, isotype rat IgG2b, R&D Systems) spe-
cific mAbs.
Flow cytometry. Analyses were performed using a Beckman-Coulter Cytomics FC-500 flow cytometer 
equipped with a single 15 mW argon ion laser operating at 488 nm and interfaced with CXP Software 2.1 and 
Beckman-Coulter GALLIOS flow cytometer equipped with a 22 mW Blue Solid State Diode laser operating at 
488 nm and with a 25 mW Red Solid State Diode laser operating at 638 nm, and interfaced with Kaluza analysis 
software. Green florescence from FITC was collected through a 525-nm bandpass filter, orange-red fluorescence 
from PE was collected through a 575-nm bandpass filter and blue fluorescence from PC7 was collected through a 
770-nm bandpass filter excited by 488 nm laser (FC-500); far-red fluorescence from APC was collected through a 
660/20-nm bandpass filter excited by 638 nm laser (GALLIOS). Two-hundred-thousand cells were acquired and 
gated on lymphocyte and monocyte forward and side scatter properties. Data were collected using linear ampli-
fiers for forward and side scatter and logarithmic amplifiers for fluorescences. Samples were first run using iso-
type control or single fluorochrome-stained preparations for color compensation. Rainbow Calibration Particles 
(Spherotec, Inc. Lake Forest, IL) were used to standardize flow-cytometry results in samples obtained over time.
Measurement of cytokines: ELISA. IL-1β, IL-6, IL-33 and human Interferon-lambda (IFN-λ)1–3 
concentration was measured in supernatants of either unstimulated or Aβ1-42-stimulated PBMC by multiplex 
sandwich immunoassays according to the manufacturer’s recommendations (Quantikine Immunoassay; R&D 
Systems). Briefly, 200 μl per well of standard, sample, or control were transferred into the IL-1β, IL-6 or IFN-λ 
antigens coated polystyrene microwells and the plates were incubated for 2 hours at room temperature. After 
three washing steps with washing buffer to remove the unbound proteins, 200 μl of Human IL-1β IL-6 or IFN-λ 
peroxidase conjugate was added to each well and incubated at room temperature for 2 hours. After re-washing 
step, 200 μl of chromogen/substrate solution were added to each well and incubated at room temperature for 
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20 min protect from light. Finally, 50 μl of stop solution were added to each well and the reaction stopped. The 
wells were read on a plate reader (Sunrise, Tecan, Mannedorf, Switzerland) and optical densities (OD) of wells 
were determined at 450/620 nm. The measured absorbance is proportional to the concentration of cytokines 
(IL-1β or IL-6) and IFN-λ present in the supernatants expressed in pg/ml and calculated by dividing optical 
density (OD) measurement generated from the assay by OD cut-off calibrator. All the experiments were per-
formed in duplicate. Sensitivity (S) and Assay Range (AR) were as flows: S: IL-1β = 1 pg/ml, IL-6 = 0,7 pg/ml and 
IFN-λ = 50ng/ml; AR: IL-1β 3.9–250 pg/ml, IL-6 3.1–300 pg/ml, IFN-λ = 62,5–4000 ng/ml.
MRI analysis. Hippocampal volume data have been extracted for each subject from high-resolution T1 
3D images collected using a 1.5T scanner (Siemens, AVANTO) at the time of MCI diagnosis - MPRAGE; TR/
TE = 1900/3.37 ms, FoV = 192 mm × 256 mm, in-plane resolution 1 mm × 1 mm, slice thickness = 1 mm, num-
ber of axial slices = 176) using AdaBoost (see Fig. 3A), a fully-automated machine-learning segmentation 
algorithm61,62. ADABoost is a fully-automated machine-learning segmentation algorithm implementing the 
EADCADNI harmonized hippocampal segmentation protocol for Alzheimer-related pathologies, able to auto-
matically segment subcortical structures as hippocampus. Hippocampal volumetries were compared across the 
two groups (AD-converters and AD non-converters) at baseline and were also used to compute regression anal-
yses with anti-inflammatory cytokines production.
Statistical analysis. Quantitative data were not normally distributed (Shapiro-Wilk test) and are thus 
summarized as median and interquartile range (IQR; 25° and 75° percentile). Firstly, comparisons between two 
groups (AD converters and non converters) were analyzed to evaluate immunological differences; comparisons 
were made using a 2-tailed Mann-Whitney U test for independent samples. Data analysis was performed using 
the MedCalc statistical package (MedCalc Software bvba, Mariakerke, Belgium).
Secondly, we performed Kruskal-Wallis ANOVA models, adjusted for MMSE to compare right and left hip-
pocampal volume levels in the two groups of AD converters and AD non-converters. This analysis was performed 
using the package “sm” of the R software, freely available. Thirdly, separately in each group of AD-converters and 
AD non-converters, we calculated the correlations (using Spearman’s coefficient) between hippocampal volume 
levels and other immune parameters. P-values < 0.05 are reported as statistically significant in the text. Power was 
calculated with the G-power software63. Notwithstanding the small samples, effect sizes were reasonably large and 
attained power was above 0.90 for all comparisons.
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